Skip to main content
| News

Investors give Resistell 8.5 million Swiss francs

23.12.2022

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology company plans to use this to gain European certification for its test device, which uses nanotechnology to expedite the development of new antibiotics with a more specific effect.

The team of Resistell in its office in Muttenz (img: Resistell)

Resistell has received 8.5 million Swiss francs from investors. This is from the first tranche of a series B funding round. The biotech company located in Muttenz in the canton of Basel-Landschaft is planning to conclude a second round next year.

According to a press release, the funds will be used to complete clinical studies with the Resistell Phenotech diagnostic device. It uses phenotypic nanomotion technology to measure living cells, which should accelerate susceptibility testing for new antibiotics. According to Resistell’s CEO Danuta Cichocka, this provides “an innovative solution for one of the world’s largest unmet medical needs”. It allows innovative antibiotics to be developed rapidly that can deliver targeted treatments despite increasing global resistance.

Strong support from investors

The first half of a clinical study on bacteremia (bacteria in the blood) and sepsis (a life-threatening response to infection) using the Resistell test device has already been conducted at Lausanne University Hospital. According to the information provided, the clinical data shows “a massive impact on time to result and around 95% accuracy with the gold standard.”

The company, which was founded in 2018, plans to use this “strong support” from investors to gain certification in accordance with Europe’s In Vitro Diagnostic Medical Devices Regulation (IVDR). Resistell Chairperson Barbara Staeheli stated that after this, Resistell plans to commercialize its first product in the research market “and seek partnerships with the diagnostic industry, medical centers and academia for bacteremia and a broad range of other indications”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Cell and gene therapies gain momentum in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Investors give Resistell 8.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.